Upcoming Funding Opportunities:
NCI Kirschstein-NRSA Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (F31) | Applications are due April 8, Aug. 8, and Dec. 8, 2019 | PA-19-196
Diversity Research Supplements (New) | Apply between Feb. 1 – March. 30 and Oct. 1 - Dec. 1, 2019 | PA-18-586
Re-entry supplement FOA (New) | Apply between Feb. 1 – March. 30 and Oct.1 - Dec 1, 2019 | PA-18-592
Please use these updated Diversity Supplements Guidelines and Re-Entry Supplements Guidelines along with DS fact sheet to prepare your application.
NCI Mentored Research Scientist Development Award to Promote Diversity (K01) | Applications are due Feb.12, June 12, and Oct. 12, 2019 | PAR-18-364 | PAR-18-365
NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08) | Applications are due Feb.12, June 12, and Oct. 12, 2019 | PAR-18-337 | PAR-18-336
NCI Transition Career Development Award to Promote Diversity (K22) | Applications are due Feb.12, June 12, and Oct. 12, 2019 | PAR-18-366 | PAR-18-367
Exploratory/Developmental Grants Program for Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed) | Applications are due June 19 and Nov. 19, 2019 | PAR-18-655
Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed) | Application are due June 19 and Nov.19, 2018 | PAR-18-731
Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed) | Applications are due June 19 and Nov. 19, 2019 | PAR-18-654
National Cancer Institute Youth Enjoy Science Research Education Program (R25) | Application are due September 25, 2019 | PAR-17-059
Other Non-CURE Funding Opportunities
Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R01/R21 Clinical Trial Optional) | Applications are due June 5 and Oct 5, 2019 | PA-18-738 | PA-18-739
*NEW* Co-infection and Cancer (R01/R21 Clinical Trial Not Allowed) | Applications are due March 6, 2020 | PAR-20-062 | PAR-20-061
The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection.
*NEW* Mechanisms of Disparities in Chronic Liver Diseases and Cancer (R01/R21 Clinical Trials Not Allowed) | Applications due April 1, 2020 | PAR-20-088 | PAR-20-081
The purpose of the initiative is to support multidisciplinary exploratory or developmental research to understand the underlying etiologic factors and mechanisms that contribute to population-level disparities in chronic liver diseases and liver cancer in the U.S.
*NEW* Research Answers to National Cancer Institute's (NCI) Provocative Questions (R01/R21 Clinical Trial Optional) | Applications due April 30, 2020 | RFA-CA-20-004 | RFA-CA-20-005
The current issuance of the PQ Initiative includes an updated set of 9 PQs. Each research project proposed in response to this FOA must be focused on addressing the research problems defined by a specific PQ selected from the list. Projects proposed to address PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged if they serve the scientific focus of the selected PQ.
*NEW* Alzheimer’s-focused Administrative Supplements for NIH/NCI Grants that are not focused on Alzheimer’s Disease (NOT-CA-20-019 and related announcements NOT-AG-20-008 and PA-18-591): Applications due March 6, 2020
Parent grant program directors need to be involved in the process with the PIs applying to this supplement. Grantees cannot have large carryovers and must have one year or more left on their grants. Administrative supplements are due March 6 and are one-year supplements.
Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional) | Applications due date: September 10, 2019 | PA-18-842
*NEW*Administrative Supplements to Support Cancer Disparity Collaborative Research Pre-application
Due dates: February 10, 2020 and September 10, 2020 Description: If you hold an active NCI-funded R01 (with at least 2 years of support remaining) and are interested in expanding your research to incorporate a cancer disparities research project, please consider submitting a proposal under FOA PA-18-842: Administrative Supplements to Support Cancer Disparity Collaborative Research. Please note that for this FOA, collaborative teams are required between a non-cancer disparities investigator (PI of the R01) and a collaborator who has minority health research or cancer disparities research expertise.
*NEW*The Sexual & Gender Minority Research Office (SGMRO) is pleased to announce the publication of a Notice of Special Interest (NOSI) regarding Administrative Supplements for Research on Sexual and Gender Minority (SGM) Populations (NOT-OD-20-032).
Purpose: This Notice of Special Interest (NOSI) announces the availability of administrative supplements to provide funding for the expansion of existing research projects to incorporate sexual and gender minority (SGM) populations, which include, but are not limited to, those populations described in Notice NOT-OD-19-139. Basic, social, behavioral, clinical, translational, and health services research relevant to the missions of the sponsoring NIH Institutes or Centers (ICs) may be proposed in response to this solicitation. Potential applicants are also encouraged to review the FY 2017 Portfolio Analysis of NIH-funded SGM research to identify potential research gaps that may be relevant to this NOSI.
Application Due Dates are January 31, 2020 for FY 2020, January 25, 2021 for FY 2021, by 5:00 PM local time of applicant organization.
NCI Community Oncology Research Program (NCORP) | Research Bases | Community Sites | Minority/Underserved Community Sites Cooperative Agreement | Application Deadline is August 31, 2019 | RFA-CA-18-015 | RFA-CA-18-016 | RFA-CA-18-017
Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) | Application due date November 7, 2019 | PAR-18-869
National Cancer Institute’s Healthcare Delivery Research Program (HDRP) supports several current funding opportunities listed down below:
Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults (R01/R21 Clinical Trial Optional) | PA-18-005 | PA-18-015
Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (R01/R21 Clinical Trial Optional) | PA-18-004 | PA-18-014
Multilevel Interventions in Cancer Care Delivery: Follow-up to Abnormal Screening Tests (R01 Clinical Trial Optional) | PA-17-495
Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R01/R21 Clinical Trial Optional) | PAR-18-246 | PAR-18-247
Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01/R21/R03 Clinical Trial Optional) | PAR-18-008 | PAR-18-019 | PAR-16-337
Using Information Technology to Support Systematic Screening and Treatment of Depression in
Oncology Practices (R01 Clinical Trial Optional) | PAR-18-493 | PAR-18-492
Mechanisms of Disparities in Etiology and Outcomes of Lung Cancer in the U.S.: The Role of Risk and Protective Factors (R21/R01 Clinical Trial Not Allowed) | Applications are due March 4, 2019, March 4, 2020, March 4, 2021| PAR-19-019 | PAR-19-018
The purpose of this initiative is to promote multidisciplinary research to understand the underlying causal factors and mechanisms that result in lung cancer disparities in U.S. health disparity populations.
Collaborative Minority Health and Health Disparities Research with Tribal Epidemiology Centers (R01 Clinical Trial Not Allowed) | Applications are due December 4, 2018 |PAR-17-484
The purpose of this initiative is to support collaborative research between Tribal Epidemiology Centers and extramural investigators on topics related to minority health and health disparities in American Indian / Alaska Native (AI/AN) populations.
Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations (R01 Clinical Trial Optional) | The FOA will open for applications on January 5, 2019 and first standard due date is February 5, 2019 | PA-18-932
This FOA invites applications that seek to understand strategies to reduce disparities by increasing the uptake of evidence-based screenings across the adult lifespan. Research supported by this initiative should enhance the screening process related to use (1) in diverse populations, (2) in diverse clinical and community settings, and/or (3) with traditional, nontraditional, and/or allied health care providers.
NIH: Small Business Innovations for Health Disparities | Letters of Intent March 1 | Deadline for application is April 1 | RFA-MD-19-001
Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20, Clinical Trials Optional) | Application are due June 19, 2019, October 18, 2019, June 19, 2020, and October 18, 2020 | RFA-CA-19-034
Purpose: The goals for this FOA include developing translational research programs focused on investigating cancer disparities. The P20 grants will support feasibility and planning activities to build cancer disparities research programs, with the expectation that the research programs will become competitive for a full P50 SPORE. Reissue of RFA-CA-17-034 (resubmissions will be accepted). New restrictions: Due to a focus on understudied areas of cancer disparities, applications proposing prostate and breast cancer projects are not responsive for this issuance.
A pre-application webinar is planned for late April. A Notice will be published on the RFA with the date and a link to registration.
New Funding Opportunities
*NEW* Notice of Special Interest (NOSI): NCI's Research Interests to Improve Interprofessional Teamwork and Coordination During Cancer Diagnosis and Treatment; NOT-CA-19-059
Contact: Sallie Weaver Application Due Date: This NOSI applies to due dates on or after September 25, 2019 through January 8, 2022. Applications related to this NOSI may be submitted using the following funding opportunity announcements or future reissuances: PAR-18-869, PAR-18-559, PA-19-056, PAR-18-290 An informational webinar is being planned. Please check our website for updates.
*NEW* Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization; PAR-19-352 (R01), PAR-19-355 (R21)
Contact: Michelle Mollica Next Submission Date: October 17, 2019 (R01); October 16, 2019 (R21) Expiration Date: September 8, 2022
*NEW* Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake; PAR-19-360 (R01), PAR-19-358 (R21), PAR-19-359 (R03)
Contact: Sarah Kobrin Next Submission Date: October 17, 2019 (R01); October 16, 2019 (R21 and R03) Expiration Date: September 8, 2022 (R01 and R21); July 17, 2022 (R03)
Software for Patient Navigation Through the Cancer Care Continuum (Topic 406): PHS2020-1 SBIR Contract Solicitation
Contact: Gurvaneet Randhawa Application Due Date: October 23, 2019
Dissemination and Implementation Research in Health, PAR-19-274 (R01), PAR-19-275 (R21), PAR-19-276 (R03)
Contact: Gila Neta, Wynne E. Norton, and David Chambers (from the DCCPS Implementation Science Team) Next Submission Date: October 5, 2019 (R01), October 16, 2019 (R21 and R03) Expiration Date: May 8, 2022
Funding Opportunity Announcement for Dissemination and Implementation Research in Health (R01/R21/R03) The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, developing, testing, evaluating and/or refining strategies to disseminate and implement evidence-based practices
New applications are due by October 5, 2019 by 5:00 PM local time of applicant organization. For more on standard applications deadlines visit: https://grants.nih.gov/grants/how-to-apply-application-guide/due-dates-and-submission-policies/due-dates.htm Program staff are available to answer questions. Contact information and funding resources are available online.
Funding Opportunity Announcement Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01/R03/R21) This FOA encourages research on how the health care delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and health care delivery.
Application Due Dates:
Sample Grant Applications The National Cancer Institute (NCI) frequently receives questions from investigators for examples of successfully funded grant applications. Several investigators and their organizations agreed to let the Division of Cancer Control & Population Sciences (DCCPS) programs post excerpts of their grant applications online.
Other Federal Grants
*NEW* CMS Minority Research Grant Program | June 2, 2020 | CMS-1W1-20-001
The Office of Minority Health at the Centers for Medicare and Medicaid Services (CMS) will make two awards of $250,000 each to support research at minority-serving institutions. Eligible applicants are public and private institutions of higher education that can enhance CMS capacity for reducing health disparities in minority populations.
Looking for additional funding opportunities? A full list of CRCHD funding opportunities as well as select NIH opportunities is available online.